SAR study of 1-aryl-4-(phenylarylmethyl)piperazines as ligands for both dopamine D2 and serotonin 5-HT1A receptors showing varying degrees of (Ant)agonism. Selection of a potential atypical antipsychotic

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 9, 2006, Pages 1326-1330

  Feenstra, Roelof Willem ^a   Van Den Hoogenband, Adri ^a   Stroomer, Cornelis Nicolaas Jozef ^a   Van Stuivenberg, Herman Heinrich ^a   Tulp, Martin Theodorus Maria ^a   Long, Stephen Kenneth ^a   Van Der Heyden, Johannes Antonius Maria ^a   Kruse, Cornelis Gerrit ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

(Partial) dopamine D2 receptor antagonist; (Partial) serotonin 5 HT1A receptor agonist; Atypical antipsychotic; Biaryl; N phenylpiperazines; SLV313

Indexed keywords

1 ARYL 4 (PHENYLARYLMETHYL) PIPERAZINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PIPERAZINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; DOGS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; INJECTIONS, INTRAVENOUS; LIGANDS; MALE; MOLECULAR STRUCTURE; PIPERAZINES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748449034     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.1326     Document Type: Article

References (33)

1. For a more extensive introduction see: Feenstra R. W., de Moes J., Hofma J. J., Kling H., Kuipers W., Long S. K., Tulp M. Th. M., van der Heyden J. A. M., Kruse C. G., Bioorg. Med. Chem. Lett., 11, 2345-2349 (2001).
2. King D. J., Eur. Neuropsychopharmacol., 8, 33-42 (1998).
3. Galletly C. A., Clark C. R., McFarlane A. C., Weber D. L., Psychiatry Res., 72, 161-166 (1997).
4. Wadenberg M.-L., Neurosci. Behav. Rev., 20, 325-339 (1996).
5. Liebman J. M., Gerhardt S. C., Gerber R., Psychopharmacology, 97, 456-461 (1989).
6. Ellenbroek B. A., Prinssen E. P. M., Cools A. R., Eur. J. Neurosci., 6, 1-8 (1994).
7. Porsolt R. D., Anton G., Blaver N., Jaffre M., Eur. J. Pharmacol., 47, 379-391 (1978).
8. Feenstra R. W., Kruse C. G., Tulp M. Th. M., Kuipers W., Long S. K., Patent WO97/36893 (1997) [Chem. Abstr., 127, 331506 (1997)].
9. Pridgen N. P., J. Heterocycl. Chem., 12, 443-444 (1975).
10. Creese I., Schneider R., Snyder S. H., Eur. J. Pharmacol., 46, 377-381 (1977).
11. Gozlan H., El Mestikawy S., Pichet L., Glowinsky J., Hamon M., Nature (London), 305, 140-142 (1983).
12. Protais P., Costentin J., Schwartz J. C., Psychopharmacology (Berlin), 50, 1-6 (1976).
13. Van der Heyden J. A. M., Bradford D., Behav. Brain Res., 31, 61-67 (1988).
14. Berendsen H. H. G., Jenck F., Broekkamp C. L. E., Pharmacol. Biochem. Behav., 33, 821-827 (1989).
15. Bronzova J. B., Feenstra R. W., Glennon J. C., McCreary A. C., van Randen J., Ronken E., van Scharrenburg G., Patent WO 03068207 (2003) [Chem. Abstr., 139, 173826 (2003)].
16. Zeng X.-P., Le F., Richelson E., Eur. J. Pharmacol., 321, 349-354 (1997).
17. van Steen B. J., van Wijngaarden I., Ronken E., Soudijn W., Bioorg. Med. Chem. Lett., 8, 2457-2462 (1998), note 7.
18. Lipinsky C. A., Lombardo F., Dominy B. W., Feeny P. J., Adv. Drug Delivery, 23, 3-25 (1997).
19. ow in the range 2.1-5.7.
20. Veber D. F., Johnson S. R., Cheng H.-J., Smith B. R., Ward K. W., Kopple K. D., J. Med. Chem., 45, 2615-2623 (2002).
21. Kelder J., Grootenhuis P. D. J., Bayada D. M., Delbressine L. P. C., Ploemen J.-P., Pharm. Res., 16, 1514-1519 (1999).
22. Lin J. H., Drugs Today, 40, 5-22 (2004).
23. 0→∞ values after oral administration (1.5 mg/kg, n=4) and intravenous administration (0.3 mg/kg, n=3).
24. The brain and plasma levels of (4e) in rats were determined after repeated oral dosing (28 mg/kg, n=10+10 male and female) for 28 d, from which the brain/plasma ratio was calculated.
25. Hartog J., Olivier B., van Wijngaarden I., Kruse C. G., van der Heyden J. A. M., van Dalen van der As D. A., Patent EP0189612 (1986) [Chem. Abstr., 106, 5080 (1986)].
26. Feenstra R. W., den Hartog J. A. J., Kruse C. G., Tulp M. Th. M., Long S. K., Patent EP 0908458 (1999) [Chem. Abstr., 130, 282087 (1999)].
27. Maerten E., Hassouna F., Couve-Bonnaire S., Mortreux A., Carpentier J.-F., Castanet Y., Synlett, 12, 1874-1876 (2003).
28. Arlt M., Bottcher H., Riethmuller A., Schneider G., Bartoszyk G. D., Greiner H., Bioorg. Med. Chem. Lett., 8, 2033-2038 (1998).
29. Iqbal N., Akula M. R., Vo D., Matowe W. C., McEwen C.-A., Wolowyk M. W., Knaus E. E., J. Med. Chem., 41, 1827-1837 (1998).
30. Gellibert F. J., Mathews N., Patent WO 2002066462 (2002) [Chem. Abstr., 137, 201305 (2002)].
31. Feuerstein M., Doucet H., Santelli M., J. Organomet. Chem., 687, 327-336 (2003).
32. Gran U., Tetrahedron, 59, 4304-4308 (2003).
33. Dorsch D., Boettcher H., Arlt M., Gottschlich R., Seyfried C., Bartoszyk G., Harting J., Patent WO 2001098293 (2001) [Chem. Abstr., 136, 53688 (2001)].